Search Results for "triptans"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for triptans. Results 21 to 24 of 24 total matches.
See also: Maxalt

Ziprasidone (Geodon) For Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001  (Issue 1106)
dopamine and serotonin receptor antagonist, ziprasidone is also a serotonin receptor agonist ...
Ziprasidone (Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.
Med Lett Drugs Ther. 2001 Jun 11;43(1106):51-2 |  Show IntroductionHide Introduction

Liraglutide (Saxenda) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
caps 120 mg tid 2.5-3.4 kg8 512.10 Alli9 (GSK) 60 mg caps 60 mg tid 44.00 Serotonin Receptor Agonist ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza, has now also been approved at a higher dose as Saxenda (Novo Nordisk) for chronic weight management in adults with a BMI ≥30, or a BMI ≥27 with a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):89-90 |  Show IntroductionHide Introduction

Atogepant (Qulipta) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
-related migraine headaches can sometimes be prevented with use of an NSAID or a triptan (particularly ...
Atogepant (Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Med Lett Drugs Ther. 2021 Nov 1;63(1636):169-71 |  Show IntroductionHide Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
adverse effects iSerotonin receptor agonists such as ondansetron (Zofran, and others ...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 |  Show IntroductionHide Introduction